102 related articles for article (PubMed ID: 6237460)
1. Effects of BM 13.177, a new antiplatelet drug in patients with atherosclerotic disease.
Riess H; Hiller E; Reinhardt B; Bräuning C
Thromb Res; 1984 Aug; 35(4):371-8. PubMed ID: 6237460
[TBL] [Abstract][Full Text] [Related]
2. Platelet half-life in comparison to other in-vivo platelet function parameters such as thromboxane B2, beta-thromboglobulin and platelet factor 4 in patients with atherosclerotic lesions with and without hyperlipoproteinemia.
Strobl-Jäger E; Fitscha P; Kaliman J; Widhalm K; Sinzinger H
Vasa; 1986; 15(4):373-8. PubMed ID: 2948337
[No Abstract] [Full Text] [Related]
3. Thromboxane receptor blockade versus cyclooxigenase inhibition: antiplatelet effects in patients.
Riess H; Höfling B; von Arnim T; Hiller E
Thromb Res; 1986 Apr; 42(2):235-45. PubMed ID: 3012819
[TBL] [Abstract][Full Text] [Related]
4. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase.
Reilly IA; Doran JB; Smith B; FitzGerald GA
Circulation; 1986 Jun; 73(6):1300-9. PubMed ID: 2938849
[TBL] [Abstract][Full Text] [Related]
5. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
6. The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug.
Stegmeier K; Pill J; Müller-Beckmann B; Schmidt FH; Witte EC; Wolff HP; Patscheke H
Thromb Res; 1984 Aug; 35(4):379-95. PubMed ID: 6385334
[TBL] [Abstract][Full Text] [Related]
7. Effects of long-acting propranolol and verapamil on blood pressure, platelet function, metabolic and rheological properties in hypertension.
Ding YA; Chou TC; Lin KC
J Hum Hypertens; 1994 Apr; 8(4):273-8. PubMed ID: 8021907
[TBL] [Abstract][Full Text] [Related]
8. [Effects of 2 doses of lysine acetylsalicylate on platelet aggregation, beta-thromboglobulin and platelet factor 4 in aged atherosclerotic patients].
Roussel B; Delobel J; Sangosse J; Dieval J; Claisse JF; Lienard J
Therapie; 1988; 43(4):267-71. PubMed ID: 2973148
[No Abstract] [Full Text] [Related]
9. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion.
Hornby EJ; Foster MR; McCabe PJ; Stratton LE
Thromb Haemost; 1989 Jun; 61(3):429-36. PubMed ID: 2529661
[TBL] [Abstract][Full Text] [Related]
10. [Effect of chuan-xiong granules on platelet aggregation, plasma beta-thromboglobulin, platelet factor IV, thromboxane B2 and 6-keto-prostaglandin F1 alpha in coronary disease patients].
Yu Z; Chen KJ
Zhong Xi Yi Jie He Za Zhi; 1987 Jan; 7(1):8-11, 3. PubMed ID: 2954711
[No Abstract] [Full Text] [Related]
11. Platelet thromboxane synthesis and release reactions in myeloproliferative disorders.
Smith IL; Martin TJ
Haemostasis; 1982; 11(2):119-27. PubMed ID: 6211399
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs.
Davì G; Pinto A; Francavilla G; Paterna S; Campisi D; Strano A
Thromb Res; 1985 Oct; 40(2):275-81. PubMed ID: 2933846
[No Abstract] [Full Text] [Related]
13. [Antiaggregant effect and tolerance of calcium carbasalate administrated immediately after aorto-coronary bypass. Results of a double-blind versus placebo study].
Mathieu P; Villemot JP; Stoltz JF; Scheck F; Garnier LF
Pathol Biol (Paris); 1996 Jun; 44(6):571-80. PubMed ID: 8977914
[TBL] [Abstract][Full Text] [Related]
14. Intraoperative management of patients with heparin-induced thrombocytopenia.
Kappa JR; Fisher CA; Todd B; Stenach N; Bell P; Campbell F; Ellison N; Addonizio VP
Ann Thorac Surg; 1990 May; 49(5):714-22; discussion 723. PubMed ID: 1692679
[TBL] [Abstract][Full Text] [Related]
15. Effects of nisoldipine on cytosolic calcium, platelet aggregation, and coagulation/fibrinolysis in patients with coronary artery disease.
Fujinishi A; Takahara K; Ohba C; Nakashima Y; Kuroiwa A
Angiology; 1997 Jun; 48(6):515-21. PubMed ID: 9194537
[TBL] [Abstract][Full Text] [Related]
16. Central haemodynamic and antiplatelet effects of iloprost--a new prostacyclin analogue--in acute myocardial infarction in man.
Swedberg K; Held P; Wadenvik H; Kutti J
Eur Heart J; 1987 Apr; 8(4):362-8. PubMed ID: 2440682
[TBL] [Abstract][Full Text] [Related]
17. Influence of triflusal on platelet activation after coronary artery bypass graft.
Prieto MA; De La Cruz JP; Del Prado MF; Sánchez de la Cuesta F
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):191-7. PubMed ID: 10759013
[TBL] [Abstract][Full Text] [Related]
18. Phenothiazine compounds enhance phentolamine effects on platelet aggregation and thromboxane B2 production.
Anfossi G; Trovati M; Mularoni E; Massucco P; Cavalot F; Mattiello L; Emanuelli G
Arch Int Pharmacodyn Ther; 1990; 307():142-61. PubMed ID: 1982777
[TBL] [Abstract][Full Text] [Related]
19. A double blind study of prostacyclin in cardiopulmonary bypass surgery.
Walker ID; Davidson JF; Faichney A; Wheatley DJ; Davidson KG
Br J Haematol; 1981 Nov; 49(3):415-23. PubMed ID: 6457624
[TBL] [Abstract][Full Text] [Related]
20. Dose- and time-dependent antiplatelet effects of aspirin.
Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
